A Phase 1 interventional study of BAT5906 injection in Age-related Macular Degeneration, sponsored by Bio-Thera Solutions. Completed at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Bio-Thera Solutions · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.
Among the 106 studies in Macular Degeneration with a site in China, this one is the 69th largest by enrollment of the 91 interventional ones that give a count, is one of 10 that started in 2018, is one of 20 in phase 1, and was the 36th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:
West China Hospital · Sites in China
Ages 50–85
Novartis Pharmaceuticals · Sites in China, United States, Argentina and 16 more countries
Ages 50+
Innostellar Biotherapeutics Co.,Ltd · Sites in China
Ages 50–80
Innovent Biologics Technology Limited (Shanghai R&D Center) · Sites in China
Ages 50+
Peking University People's Hospital · Sites in China
Ages 50+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
106 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 36 · Phase 3 22 · Phase 4 5
First in 2008; this study’s year is marked. 10 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 62 across the 91 interventional studies, 300 across the 15 observational. Of the 39 that completed or were terminated, 6 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 106 have an industry lead sponsor. The 10 most frequent:
Bio-Thera Solutions is the lead sponsor of 57 studies on the registry; 4 are open to participants now.
Bio-Thera Solutions has 3 studies filed under Macular Degeneration — fewer than ten, so there is no comparison to draw.
11 of the studies in Macular Degeneration with a site in China that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05972473Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD | 2027-02-28 |
| NCT07189169Phase 3Smilebiotek Zhuhai LimitedQA108 Phase III Study in Subjects With Intermediate AMD | 2027-03-01 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT07053358Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSafety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients | 2026-11-23 |
| NCT07409389The Hong Kong Polytechnic UniversityRepeated Low-Level Red-Light Therapy in Dry Age-Related Macular Degeneration | 2026-12-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 106 studies in Macular Degeneration with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Phase I Clinical Trial for BAT5906(single-dose;for injection) on Safety and Pharmacokinetics for Patients with Age-related macular degeneration.
The primary objective: To evaluate the safety and Pharmacokinetics of BAT5906 (single-dose Ophthalmic Intracireal Iinjection) in patients wAMD , when the injection dosage escalates.
The Secondary objective: To evaluate the immunogenicity profile of BAT5906; To evaluate the pharmacodynamics and therapeutic efficacy profile of BAT5906.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
hyperthyroidism, hypothyroidism,vitiligo, dry-syndrome, ankylosing spondylitis, systemic nephritis, (HIV).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single dose escalation starting from 0.3mg. Route of administration: intravitreal injection.
Drug: BAT5906 injection
Signal dose escalation starting from 0.3mg. Route of administration: intravitreal injection
Also known as: No Other Intervention Names
Dose-limiting toxicity(DLT)
Safety and tolerability endpoint
Time frame: 2 weeks
Maximum tolerated dosed(MTD)
Safety and tolerability endpoint
Time frame: 0-70days
Area under the curve(AUC0-t, AUC0-inf)
Pharmacokinetic endpoint Pharmacokinetic endpoint
Time frame: 0-70days
Maximum serum drug concentration(Cmax)
Pharmacokinetic endpoint Pharmacokinetic endpoint
Time frame: 0-70days
Half-life period(t1/2)
Pharmacokinetic endpoint
Time frame: 0-70days
Maximum serum drug time(Tmax)
Pharmacokinetic endpoint
Time frame: 0-70days
Plasma clearance(CL)
Pharmacokinetic endpoint
Time frame: 0-70days
Anti-drug antibodies(ADA)
Immunogenic endpoint
Time frame: 0-70days
Best correct vision(BCVA)
Effective endpoint
Time frame: 0-70days
Central Retinal thickness(CRT)
Effective endpoint
Time frame: 0-70days
VEGF concentration
Pharmacodynamics endpoint
Time frame: 0-70days
Ran from Oct 2018 to primary completion in Feb 2021, 27 months.
Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 27 months is above that.
Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BAT5906